- Home
- WSC vs FDMT Comparison
WSC vs FDMT Comparison
Compare WSC & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WSC | FDMT |
|---|---|---|
| Founded | 1944 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 391.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | WSC | FDMT |
|---|---|---|
| Price | $20.34 | $10.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $25.43 | ★ $30.33 |
| AVG Volume (30 Days) | ★ 4.0M | 737.9K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | ★ 816.06 | N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $2,317,990,000.00 | $120,000.00 |
| Revenue This Year | N/A | $21,181.08 |
| Revenue Next Year | N/A | $162.43 |
| P/E Ratio | $17.00 | ★ N/A |
| Revenue Growth | N/A | ★ 605.88 |
| 52 Week Low | $14.91 | $2.24 |
| 52 Week High | $39.61 | $12.34 |
Technical Indicators
Market Signals| Indicator | WSC | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 53.25 |
| Support Level | $20.08 | $10.30 |
| Resistance Level | $21.45 | $11.50 |
| Average True Range (ATR) | 0.96 | 0.70 |
| MACD | 0.30 | -0.02 |
| Stochastic Oscillator | 67.79 | 56.85 |
Price Performance
Historical ComparisonAbout WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services onsite, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company includes modular office complexes, mobile offices, portable storage containers, and others.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.